… molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA …
… molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA …
… molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA …
… is a Certified Public Auditor (Register Accountant, RA) graduate from the Erasmus University Rotterdam (2004). Sheila … Team Peter Beal, PhD Peter was appointed as ProQR's Chief ADAR Scientist in December 2024. Peter is a Professor in the … For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of …
Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
… Strategic collaborations like this can help to drive the advancement of an early-stage technology, like Axiomer, … expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner … partnership is another validation of our leadership in ADAR-mediated RNA editing, our robust IP estate, and the …
